These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 23178489)

  • 1. The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents.
    Lin MZ; Marzec KA; Martin JL; Baxter RC
    Oncogene; 2014 Jan; 33(1):85-96. PubMed ID: 23178489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gefitinib radiosensitizes stem-like glioma cells: inhibition of epidermal growth factor receptor-Akt-DNA-PK signaling, accompanied by inhibition of DNA double-strand break repair.
    Kang KB; Zhu C; Wong YL; Gao Q; Ty A; Wong MC
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e43-52. PubMed ID: 22516386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage.
    Marzec KA; Lin MZ; Martin JL; Baxter RC
    Oncotarget; 2015 Sep; 6(29):26583-98. PubMed ID: 26378048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839).
    Friedmann B; Caplin M; Hartley JA; Hochhauser D
    Clin Cancer Res; 2004 Oct; 10(19):6476-86. PubMed ID: 15475435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
    Knowlden JM; Jones HE; Barrow D; Gee JM; Nicholson RI; Hutcheson IR
    Breast Cancer Res Treat; 2008 Sep; 111(1):79-91. PubMed ID: 17902048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-beta tumor-suppressor gene in breast cancer cells.
    Grunt TW; Tomek K; Wagner R; Puckmair K; Zielinski CC
    Differentiation; 2007 Nov; 75(9):883-90. PubMed ID: 17608728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. K-RAS(V12) induces autocrine production of EGFR ligands and mediates radioresistance through EGFR-dependent Akt signaling and activation of DNA-PKcs.
    Minjgee M; Toulany M; Kehlbach R; Giehl K; Rodemann HP
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1506-14. PubMed ID: 21985943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer.
    de Silva HC; Lin MZ; Phillips L; Martin JL; Baxter RC
    Cell Mol Life Sci; 2019 May; 76(10):2015-2030. PubMed ID: 30725116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylation by DNA-dependent protein kinase is critical for apoptosis induction by insulin-like growth factor binding protein-3.
    Cobb LJ; Liu B; Lee KW; Cohen P
    Cancer Res; 2006 Nov; 66(22):10878-84. PubMed ID: 17108124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity.
    Dittmann K; Mayer C; Rodemann HP
    Radiother Oncol; 2005 Aug; 76(2):157-61. PubMed ID: 16024112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
    Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining.
    Kriegs M; Kasten-Pisula U; Rieckmann T; Holst K; Saker J; Dahm-Daphi J; Dikomey E
    DNA Repair (Amst); 2010 Aug; 9(8):889-97. PubMed ID: 20615764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin.
    Ciszewski WM; Tavecchio M; Dastych J; Curtin NJ
    Breast Cancer Res Treat; 2014 Jan; 143(1):47-55. PubMed ID: 24292814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
    Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
    Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A targeted inhibition of DNA-dependent protein kinase sensitizes breast cancer cells following ionizing radiation.
    Kim CH; Park SJ; Lee SH
    J Pharmacol Exp Ther; 2002 Nov; 303(2):753-9. PubMed ID: 12388662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
    Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
    Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between antiapoptotic molecules and metastatic potency and the involvement of DNA-dependent protein kinase in the chemosensitization of metastatic human cancer cells by epidermal growth factor receptor blockade.
    Um JH; Kwon JK; Kang CD; Kim MJ; Ju DS; Bae JH; Kim DW; Chung BS; Kim SH
    J Pharmacol Exp Ther; 2004 Dec; 311(3):1062-70. PubMed ID: 15273254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.